Introduction to Who Is Eligible for a Dupixent Cancer Lawsuit
- Who Is Eligible for a Dupixent Cancer Lawsuit? If you who were prescribed Dupixent and were subsequently diagnosed with T-Cell Lymphoma or experienced other severe Dupixent side effects, call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation as you may qualify for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected].
- Dupixent Cancer Lawsuit: Numerous lawsuits have been filed against Sanofi and Regeneron, the makers of Dupixent, alleging the company failed to adequately warn patients and doctors about a potential link between the drug and the development of cutaneous T-cell lymphoma (CTCL).
- Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases. The medicine is currently the subject of a growing number of lawsuits alleging it causes or accelerates the development of cutaneous T-cell lymphoma (CTCL), a rare form of cancer. As of November 2025, the litigation is in early stages, with no settlements or jury verdicts yet.
- Recent studies on Dupixent and Cancer: Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.

The Allegations and Claims in a Dupixent Cancer Lawsuit
-
Failure to warn: Lawsuits allege that the manufacturers did not adequately inform healthcare providers and patients about the risk of CTCL and other cancers linked to Dupixent.
-
Negligent manufacturing and marketing: Some lawsuits claim the companies negligently manufactured, distributed, and marketed the drug despite evidence of a link to CTCL and other cancers.
-
Masking symptoms: Plaintiffs claim the drug’s side effects, such as rashes, can mimic CTCL, causing doctors to miss the early signs of cancer and delaying proper treatment.

The Basis for a Dupixent Cancer Lawsuit
- Primary Basis Dupixent and Cancer Lawsuits: The central claim in the lawsuits is “failure to warn“. Plaintiffs argue that the manufacturers knew or should have known about the potential link between Dupixent and CTCL based on emerging medical studies and adverse event reports, yet did not update the product’s warning label.
- Key Points: Critical points supporting the litigation include:
-
- Medical Studies: Multiple peer-reviewed studies published in 2024 and 2025 have suggested an increased risk of CTCL among Dupixent users. Some studies reported that Dupixent patients had a 300% to 450% higher risk of developing CTCL compared to non-users.
-
- FDA Investigation: In March 2025, the U.S. Food and Drug Administration (FDA) identified CTCL as a “potential signal of a serious risk” associated with Dupixent and opened a formal safety investigation. The FDA is currently evaluating whether to require a label change.
-
- Masking Symptoms: CTCL often initially appears as skin patches that can be mistaken for eczema. Lawsuits allege that Dupixent’s mechanism of action may “unmask” a pre-existing, undiagnosed lymphoma or accelerate its progression, delaying proper cancer diagnosis and treatment.
-
- First Wrongful Death Suit: A wrongful death lawsuit was filed in October 2025 by the family of a Tennessee woman who died from T-cell lymphoma shortly after starting Dupixent treatment, marking a significant development in the litigation.
Current Status of Dupixent and Cancer Lawsuits
- Individual Lawsuits:Dupixent and cancer lawsuits are in the early stages, with individual lawsuits being filed across the United States.
- No Class Action or MDL (Yet): There is currently no class action lawsuit or multidistrict litigation (MDL) for Dupixent cases, as the damages are considered too severe and unique to each patient for a single class action. However, consolidation into an MDL is possible as more cases are filed.
- No Recalls or Settlements: As of November 2025, the FDA has not recalled Dupixent, and no settlements or jury verdicts have been reached.

Who Can Qualify for a Dupixent Cancer Lawsuit?
- Eligibility: Individuals who used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL) or related T-cell lymphomas (such as mycosis fungoides or Sézary syndrome) or other severe Dupixent side effects may be eligible to file a personal injury or wrongful death lawsuit.
- Contact Dupixent Cancer Lawyer Timothy L. Miles: If you or a loved one developed CTCL after using Dupixent, or suffered other severe Dupixent side effects it is recommended to consult with a personal injury attorney promptly, as state laws impose strict deadlines (statutes of limitations) for filing a claim. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].
What are the potential benefits of a Dupixent Cancer Lawsuit?
If you are eligible for a Lawsuit, you may be entitled to substantial compensation for your medical treatment and for your pain and suffering.
How long will the Dupixent Cancer Lawsuit take to resolve?
The duration of lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.
What Is Cutaneous T-cell lymphoma?
Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing cancer of the T-cells (a type of white blood cell) that affects the skin. Symptoms often include itchy, scaly rashes, red patches, plaques, or tumors, and can mimic other skin conditions like eczema, which can delay diagnosis. In some cases, the cancer can spread from the skin to the lymph nodes or other organs. phagitis.
Key characteristics
-
What it is: A type of non-Hodgkin lymphoma that starts in T-cells in the skin.
-
Common symptoms:
-
-
Itchy, scaly patches or plaques
-
-
-
Redness on the skin
-
-
-
Thicker, raised lesions or tumors
-
-
-
Sometimes, the skin redness can cover a large portion of the body, a condition called erythroderma
-
-
Progression: CTCL is often slow-growing, but some types can be aggressive and spread to other parts of the body, such as the lymph nodes, blood, or organs like the liver or lungs.
Common types: The two most common types are mycosis fungoides and Sézary syndrome.
-
Diagnosis: Diagnosis can be challenging due to similar-looking symptoms and often involves a skin biopsy, physical exam, blood tests, and imaging.
-
Treatment: Treatments are chosen based on the stage of the cancer and can include creams, light therapy, radiation, or systemic treatments like chemotherapy or other medications.
What is cutaneous T-cell lymphoma (CTCL)?
Cutaneous T-cell lymphomas (CTCL) are a wide range and group of extremely rare cancers. Some forms grow slowly and stay in the skin. Less frequently, the cancer can spread from the skin to the blood or a lymph node. Dermatologists often work closely with oncologists (doctors who treat cancer) and other specialists to care for patients who have one of these cancers.
How many different types of CTCL are there?
There are several types. The most common types of cutaneous T-cell lymphoma, also known as CTCL cancer or CTCL, are:
-
Mycosis Fungoide (MF) – The most common type, characterized by patches, plaques, and tumors on the skin.
-
Sézary Syndrome (SS) – A more aggressive form of MF that affects the blood as well as the skin.
Other more rare types of CTCL include:
-
Lymphomatoid papulosis – A benign form of CTCL that causes small, itchy bumps on the skin.
-
Granulomatous slack skin – A rare, indolent form of CTCL that causes loose, pendulous folds of skin.
-
Anaplastic large cell lymphoma – An aggressive form of CTCL that can spread to other organs.
-
Extranodal NK/T-cell lymphoma: A rare type of CTCL that affects the skin and lymph nodes.
-
Extranodal NK/T-cell lymphoma, nasal type – A rare, aggressive lymphoma that can affect the skin, among other places.
-
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) – A rare, slow-growing type that causes nodules deep in the fatty layer of the skin, most often on the legs.
-
Primary cutaneous peripheral T-cell lymphoma (unspecified) – This is a category for rare entities that do not fit into other classifications.


